Ono Pharmaceutical Co. / Bristol-Myers Squibb Company / Bristol-Myers Squibb / MD Anderson / /
Country
Taiwan / Japan / United States / /
Event
FDA Phase / /
Facility
The University of Texas MD Anderson Cancer Center / /
IndustryTerm
treatment of patients with unresectable melanoma / treatment of cancer / treatment of patients with Hodgkin lymphoma / cancer treatment / manufacturing / /
MedicalCondition
leukemia / tumor / advanced disease / unresectable melanoma / cancer / NSCLC / myelodysplastic syndrome / chronic lymphocytic leukemia / Opdivo (nivolumab) Cancer / acute and chronic leukemia / hematologic malignancies / advanced melanoma / Hodgkin lymphoma / melanoma / glioblastoma and non-Hodgkin lymphoma / specific disease / head and neck cancer / renal cell carcinoma / chronic myeloid leukemia / acute myeloid leukemia / myelofibrosis / lung cancers / metastatic melanoma / select hematologic malignancies / /
MedicalTreatment
immunotherapies / Immunotherapy / radiation / /
Organization
EMA’s Committee for Medicinal Products for Human Use / European Medicines Agency / FDA / European Union / University of Texas / /
Person
Ron DePinho / Francis Cuss / Hagop Kantarjian / /
Position
President / chair / executive vice president and chief scientific officer / /
Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration MD Anderson News ReleaseBristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center to